Ruben Bill

Ruben Bill

Auto-generated profile, based on publicly available information

Ruben Bill

Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2023 in Science
Verified
Journal Article
Closed access
RBRuben Bill
Ruben Bill
PWPratyaksha Wirapati
Pratyaksha Wirapati
MMMarius Messemaker
Marius Messemaker
WRWhijae Roh
Whijae Roh
BZBeatrice Zitti
Beatrice Zitti
MPMikael J. Pittet
Mikael J. Pittet
Tumor microenvironments (TMEs) influence cancer progression but are complex and often differ between patients. Considering that microenvironment variations may reveal rules governing intratumoral cellular programs and disease outcome, we focused on tumor-to-tumor variation to examine 52 head and neck squamous cell carcinomas. We found that macrophage polarity—defined by CXCL9 and SPP1 (CS) expression but not by conventional M1 and M2 markers—had a noticeably strong prognostic association. CS macrophage polarity also identified a highly coordinated network of either pro- or antitumor variables, which involved each tumor-associated cell type and was spatially organized. We extended these findings to other cancer indications. Overall, these results suggest that, despite their complexity, TMEs coordinate coherent responses that control human cancers and for which CS macrophage polarity is a relevant yet simple variable.

18 December 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
GGGenevieve M. Gerhard
Genevieve M. Gerhard
RBRuben Bill
Ruben Bill
MMMarius Messemaker
Marius Messemaker
AKAllon M. Klein
Allon M. Klein
MPMikael J. Pittet
Mikael J. Pittet
Dendritic cells (DCs) contribute a small fraction of the tumor microenvironment but are emerging as an essential antitumor component based on their ability to foster T cell immunity and immunotherapy responses. Here, we discuss our expanding view of DC heterogeneity in human tumors, as revealed with meta-analysis of single-cell transcriptome profiling studies. We further examine tumor-infiltrating DC states that are conserved across patients, cancer types, and species and consider the fundamental and clinical relevance of these findings. Finally, we provide an outlook on research opportunities to further explore mechanisms governing tumor-infiltrating DC behavior and functions.

6 November 2023 in Head and Neck Pathology
Verified
Journal Article
Closed access
PDF file
RBRuben Bill
Ruben Bill
WFWilliam Faquin
William Faquin
SPSara I. Pai
Sara I. Pai

7 July 2021 in Cancer Reports
Verified
Journal Article
Open access
PDF file
RBRuben Bill
Ruben Bill
DDDaniel G. Deschler
Daniel G. Deschler
MPMikael J. Pittet
Mikael J. Pittet
SPSara I. Pai
Sara I. Pai
PSPeter M. Sadow
Peter M. Sadow
JPJong Chul Park
Jong Chul Park
Background: Secretory carcinoma is a more recently described subtype of salivary gland carcinoma that may pose diagnostic challenges and frequently harbors NTRK fusions that may successfully be targeted by TRK inhibitors in advanced disease.Case: We present the case of a female patient with secretory carcinoma arising in the base of tongue with persistent disease after debulking surgery and definitive chemoradiation. As an alternative to salvage surgery, which would have resulted in significant impairment of swallowing and speech function, a targeted therapy with the TRK‐inhibitor larotrectinib against an identified ETV6‐NTRK3 fusion product was initiated. Larotrectinib treatment has been well tolerated, resulted in durable complete response and the patient maintains good swallowing and speech function.Conclusion: The presented case underscores the importance of the accurate diagnosis of secretory carcinoma. It further highlights the impact of molecular testing as targeted therapies may play an important role in the management of advanced salivary gland cancers.

14 May 2018 in Hepatology
Verified
Journal Article
Closed access
PDF file
RBRuben Bill
Ruben Bill
MMMatteo Montani
Matteo Montani
BBBenedikt Blum
Benedikt Blum
JDJean-François Dufour
Jean-François Dufour
RERobert Escher
Robert Escher
MBMichael Bühlmann
Michael Bühlmann

11 September 2026 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
AHAnne-Murielle Hollinger
Anne-Murielle Hollinger
RBRuben Bill
Ruben Bill
Endocrine treatment in combination with CDK4/6 inhibitors represents the mainstay of first-line palliative treatment in HR+/HER2– breast cancer. The treatment landscape after progression on CDK4/6 inhibitors has evolved into a complex and rapidly evolving field, driven by novel endocrine and targeted agents, new combination therapies, and increasing implementation of biomarker-directed approaches. Recent randomized trials have shown that new therapeutic strategies significantly prolong progression-free survival in this setting, with some treatments reaching notable numerical improvements. Translating these options into routine clinical practice remains challenging due to heterogeneous trial designs, lack of head-to-head comparisons, suboptimal comparator treatments, and limited overall survival data. While the increasing implementation of biomarkers holds the potential for more personalized treatments, their clinical utility depends on their mechanistic and contextual biological relevance, methodological reliability of detection, and proven predictive value in clinical trials. Based on the current evidence, optimal treatment selection and sequencing in the post-CDK4/6 inhibitor setting remain insufficiently defined, and optimization of biomarker-guided treatment requires further mechanistic understanding and methodological refinement. This narrative review provides an overview of the most recent randomized clinical trial evidence shaping current clinical practice and discusses persistent uncertainties regarding its implementation in routine care.